Bridge Financing: The Round Boards Treat as Paperwork
Boards apply serious process to priced rounds. There is a term sheet, a valuation discussion, counsel on both sides, a board meeting devoted to it, and a sense of occasion appropriate to setting the company's value and diluting its owners.
Bridges get none of that. A bridge is small. It is urgent — that is usually why it exists. It is documented on a short form that counsel can turn around in days. It is frequently funded by the investors already on the cap table, which makes it feel less like a negotiation than a favor. And because it is explicitly temporary, it carries an implicit promise that the real decisions are being deferred to the real round later.
That combination makes bridge financing the least-governed significant decision most clinical-stage boards make. It is also, frequently, the decision that determines what the next round looks like — who participates, at what effective price, and whether new investors are willing to come in at all. The terms that felt provisional turn out to have been the terms.
This article is about governing the bridge as what it is rather than what it feels like.
Bridging to What?
The first and most important question is the one the word itself invites and boards routinely skip: a bridge to what?
A bridge is a loan against a future event. It is appropriate when the company has an identifiable landing point — a data readout that will reprice the company, a partnership in late-stage negotiation, a priced round with real interest that needs a few months to close, a regulatory milestone — and needs to reach it. The financing makes sense because the event is plausible and because reaching it is worth more than the cost of the bridge.
A bridge is not appropriate as a general-purpose extension of a company whose situation will be no different in six months than it is today. The industry's own vocabulary is unkind but accurate here: a bridge to nowhere is a pier. Money goes in, time passes, the company arrives at the same place with a more complicated cap table and less credibility.
So the board's threshold question, before any discussion of terms, is what specifically will be true when the bridge runs out that is not true now, how confident the company is in that, and whether the bridge is long enough to actually get there. That last part matters more than it sounds: bridges are routinely sized to the minimum the insiders are willing to put in rather than to the amount required to reach the milestone, which guarantees a second conversation under worse conditions.
A board that cannot answer the landing-point question crisply is not approving a bridge. It is approving a delay, and it should at least know that is what it is doing.
The Mechanics That Actually Decide Things
Bridges are documented as convertible notes or as SAFEs and similar instruments. Either way, a handful of terms carry nearly all the consequence, and directors should understand them specifically rather than deferring to counsel's summary.
The valuation cap. This is the term boards most often misunderstand. The appeal of a bridge is supposedly that it defers the valuation question to the next priced round. A cap undoes that. It sets a maximum valuation at which the bridge converts, which means that if the next round prices above the cap, the bridge holders convert as though the company were worth the cap. In any scenario where the bridge works — where the milestone is hit and the company's value rises — the cap, not the next round's negotiated price, is the effective price the bridge investors paid. Boards that approve a bridge believing they have postponed the valuation discussion have usually just had it, quickly, without the preparation they would have brought to a priced round.
The discount. A conversion discount gives bridge holders a percentage reduction off the next round's price, compensating them for early risk. It is straightforward, but it stacks with the cap — conversion typically occurs at whichever is more favorable to the holder — and discounts compound unpleasantly across multiple bridges.
Maturity and what happens at it. A note has a maturity date, and the board should know precisely what the holders can do when it arrives if no qualified financing has occurred. Demand repayment the company cannot make? Convert at a predetermined price? Extend only with their consent? A maturity date that falls before the milestone the bridge was meant to reach is a structural error that hands the noteholders enormous leverage at exactly the company's weakest moment. This is worth checking directly rather than assuming the dates were aligned.
What counts as a qualified financing. Conversion is typically triggered by a priced round above some threshold size. Set the threshold too high and a modest but real next round fails to trigger conversion, leaving the notes outstanding. Set the definition loosely and conversion can be triggered by something the board did not intend.
Seniority and security. Notes are debt. In a liquidation or a sale, they typically sit ahead of all equity. A company carrying substantial note debt into a modest exit can find that the noteholders — usually the insiders who funded the bridge — take the proceeds before any preferred or common holder sees anything. If the notes are secured against company assets, including intellectual property, the stakes rise further. Boards should know the answer to "what happens to these notes in a sale at a disappointing price" before signing, not after.
Warrant coverage and most-favored-nation provisions. Warrants add dilution that does not appear in the headline terms. MFN clauses entitle holders to the best terms given to any subsequent bridge investor, which can retroactively improve earlier money and complicate later rounds.
The Insider Problem, in Compressed Form
Most bridges are funded by existing investors. That is natural — they know the company, they have the most to lose if it fails, and no outsider will price a round in the middle of a gap. It also means the people setting the terms, approving the terms, and benefiting from the terms are substantially the same people.
The structural conflict is identical to a conflicted priced round. What differs is the governance applied to it. A down round or an insider-led equity financing tends to trigger the full apparatus: conflicts identified, a disinterested committee, independent counsel, documented deliberation. A bridge of a quarter the size, carrying terms that will determine the insiders' position in the round that follows, often gets approved by written consent between meetings because the amount seemed small and the company needed the money that week.
The protections available are the same ones available anywhere: identify who is interested before terms are negotiated, have the disinterested directors approve the financing and record the basis for that determination, offer participation to all eligible holders on the same terms where possible, and document what alternatives were considered. None of this is onerous at bridge scale. The reason it gets skipped is not cost; it is that a bridge does not feel like the kind of event that warrants it.
There is also a specific dynamic worth naming. A bridge funded only by a subset of insiders, on terms those insiders set, operates as a pay-to-play by other means: participants improve their position relative to non-participants without the explicit conversion mechanics that would make everyone focus on what is happening. Where a bridge is being offered selectively, the board should ask why, and should be able to explain why the allocation is fair to those left out.
The Overhang Problem
The most underappreciated cost of a bridge is what it does to the round it was meant to enable.
Outstanding convertible instruments are an overhang. A new lead investor pricing the next round must account for notes that will convert into their round, often at a discount, sometimes at a cap set when the company was worth less. The new money is effectively subsidizing the bridge holders, and sophisticated investors price that in — by demanding a lower valuation, by requiring the notes be restructured, or occasionally by declining a situation they find too complicated to be worth untangling.
This effect compounds badly across multiple bridges. A company on its third bridge may be carrying three instruments with different caps, different discounts, different maturities, and possibly MFN clauses that interact. Each was reasonable in isolation. Together they can make the company genuinely difficult to finance, and the board that approved each one incrementally may never have looked at the combined picture.
Two disciplines help. First, the board should model what the cap table actually looks like after conversion, under several plausible next-round scenarios, before approving any bridge — not after. The question "who owns what, and what has the common been diluted to, if this converts at the cap in a round at these prices" is answerable in an afternoon and changes how terms are negotiated. Second, serial bridges should prompt a different conversation entirely. A third bridge is not a financing decision; it is evidence that the premise underlying the first two did not hold, and the board should treat it as a prompt to revisit the company's direction rather than as another gap to be closed.
The Questions a Board Should Ask
What specifically changes before this money runs out, and is the bridge sized to get there? Including: if the milestone slips by a quarter, as milestones do, what then?
What is the cap, and what price are we actually setting? Followed by: if the next round prices well above this cap, how much of that round do the bridge holders take?
What does the cap table look like post-conversion, under good and bad scenarios? Modeled, not assumed.
What happens at maturity if the milestone has not been reached? And does maturity fall before or after the event this bridge exists to reach?
Where do these notes sit in a sale? Specifically in a modest sale, where the answer matters most and is least pleasant.
Who is being offered participation, and who is not? With an answer the board would be comfortable giving to those excluded.
Does the overhang make the next round harder to raise? Asked of someone with no stake in the bridge closing.
The Traps
Approving by written consent under time pressure. The urgency is often real, which is precisely why the terms deserve a conversation rather than a signature. A board that is routinely asked to approve financings between meetings should ask why it is always finding out late.
Mistaking a cap for deferred valuation. The single most common misreading in this entire area.
Letting the bridge be sized by what insiders will offer rather than what the milestone requires. This guarantees a sequel.
Maturity before milestone. A structural error that is trivially avoidable and painful to live with.
Treating the third bridge as a financing question. It is a strategy question wearing a financing costume.
Skipping conflict process because the amount is small. The size of the check does not determine whether the people approving it are interested in the outcome.
The Underlying Principle
A bridge presents itself as a provisional, administrative, low-stakes act — money to get from here to there, documented simply, to be superseded by the real financing shortly. Boards govern it accordingly, and that mismatch is the whole problem.
In reality a bridge sets an effective price through its cap, creates debt that sits ahead of every shareholder in a sale, hands leverage to its holders at maturity, improves insiders' positions relative to those who do not participate, and shapes whether the next round can be raised at all. None of those consequences are provisional.
The remedy is not more process for its own sake. It is applying to a bridge the same three questions a board would apply to any priced round — what are we actually paying, who benefits and who is left out, and what does the cap table look like afterward — and refusing to let urgency substitute for the answers. A bridge is worth approving when the far side is real. It is worth governing in every case.
Lawrence Fine is CEO of AGCP Farmacêuticos and has advised on licensing, regulatory, and partnership strategy across the pharmaceutical and advanced materials sectors.